Evidence map›Paper›PMID 24604094›Full record

ArticleBreast cancer research and treatment2014

Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression.

Candyce H Kroenke, Carol Sweeney, Marilyn L Kwan, Charles P Quesenberry, Erin K Weltzien, Laurel A Habel, Adrienne Castillo, Phillip S Bernard, Rachel E Factor, Lawrence H Kushi and 1 more

Abstract read
In one paragraph

Article in Breast cancer research and treatment, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype: A Systematic Review and Meta-Analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Observational
  6. Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Epidemiology of Basal-like and Luminal Breast Cancers among Black Women in the AMBER Consortium.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021
    Article
  11. Article
  12. Review
  13. Article
  14. Atypical Chemokine Receptor 1 (Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019
    Article
  15. Article
  16. Review
  17. Breast cancer metastasis through the lympho-vascular system.Clinical & experimental metastasis · 2018
    Review
  18. Breast Cancer in Latinas: A Focus on Intrinsic Subtypes Distribution.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Candyce H KroenkeDivision of Research, Kaiser Permanente Northern California, 2000 Broadway, 5th Floor, Oakland, CA, 94612, USA, candyce.h.kroenke@kp.org.
Carol Sweeney
Marilyn L Kwan
Charles P Quesenberry
Erin K Weltzien
Laurel A Habel
Adrienne Castillo
Phillip S Bernard
Rachel E Factor
Lawrence H Kushi
Bette J Caan

Funding

Prospective Study of Breast Cancer SurvivorshipR01CA105274 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI KUSHI, LAWRENCE H · 2004 to 2014
$19.9M
Molecular Profiles and Lifestyle Factors in Breast Cancer PrognosisR01CA129059 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI CAAN, BETTE J · 2009 to 2013
$3.6M
NCI NIH HHS HHSN261201000026CNCI NIH HHS R01 CA105274NCI NIH HHS R01 CA129059
6 · The paper itself

Abstract

To evaluate whether differences in PAM50 breast cancer (BC) intrinsic (Luminal A, Luminal B, Basal-like, and HER2-enriched) subtypes help explain the Black-White BC survival disparity. Utilizing a stratified case-cohort design, this study included 1,635 women from the Pathways and Life After Cancer Epidemiology cohorts, selecting women with tumors based upon IHC classification, recurrences, and deaths.One millimeter punches were obtained from tumor tissue, and expression of the PAM50 genes for molecular subtype was determined by RT-qPCR of extracted RNA. Cox proportional hazards models were used to analyze associations between race and BC outcomes, adjusted for PAM50 BC subtype. All tests of statistical significance were two-sided. Black women had a higher prevalence of the Basal-like BC subtype. Adjusted for potential confounding variables and disease characteristics at diagnosis, Black women had higher risks of recurrence (HR 1.65, 95 % CI 1.06-2.57) and breast cancer-specific mortality (HR 1.71, 95 % CI 1.02-2.86) than White women, but adjusting further for subtype did not attenuate survival disparities. By contrast, Hispanic women had a lower risk of recurrence (HR 0.54, 95 % CI 0.30-0.96) than Whites. Among those with the Basal-like subtype, Black women had a similar recurrence risk as women in other race groups but a higher recurrence risk for all other subtypes. Hispanic women had a lower recurrence risk within each subtype, though associations were not significant, given limited power. Although Black women had a higher risk of the Basal-like subtype, which has poor prognosis, this did not explain the Black-White BC survival disparity.

Indexed as

Gene Expression ProfilingAdultAgedAged, 80 and overBiomarkersBreast NeoplasmsCaliforniaCase-Control StudiesEthnicityFemaleHumansMiddle AgedRecurrenceRegistriesRisk FactorsUtahBiomarkers

Identifiers

PMID24604094
PMCPMC4035036

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.